TW282403B - - Google Patents

Info

Publication number
TW282403B
TW282403B TW083106287A TW83106287A TW282403B TW 282403 B TW282403 B TW 282403B TW 083106287 A TW083106287 A TW 083106287A TW 83106287 A TW83106287 A TW 83106287A TW 282403 B TW282403 B TW 282403B
Authority
TW
Taiwan
Prior art keywords
protein
physiologically active
active peptide
matrix
pharmaceutical preparation
Prior art date
Application number
TW083106287A
Other languages
English (en)
Chinese (zh)
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW282403B publication Critical patent/TW282403B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
TW083106287A 1993-08-26 1994-07-12 TW282403B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23582393 1993-08-26

Publications (1)

Publication Number Publication Date
TW282403B true TW282403B (enExample) 1996-08-01

Family

ID=16991792

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083106287A TW282403B (enExample) 1993-08-26 1994-07-12

Country Status (10)

Country Link
US (2) US5628993A (enExample)
EP (1) EP0640336B1 (enExample)
JP (1) JPH07112940A (enExample)
KR (1) KR100338400B1 (enExample)
CN (1) CN1105557C (enExample)
AT (1) ATE148625T1 (enExample)
CA (1) CA2130868A1 (enExample)
DE (1) DE69401691T2 (enExample)
DK (1) DK0640336T3 (enExample)
TW (1) TW282403B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
JP4330175B2 (ja) * 1995-06-07 2009-09-16 デュレクト コーポレイション 高粘度液体による制御された送達系
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CA2276450C (en) * 1997-01-02 2013-02-19 Thomas Jefferson University A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
AU779277B2 (en) * 1999-06-04 2005-01-13 Alza Corporation Implantable gel compositions and method of manufacture
EP1949890A3 (en) 1999-06-04 2011-05-18 ALZA Corporation Implantable gel compositions and method of manufacture
JP2001058955A (ja) * 1999-06-17 2001-03-06 Inst Of Physical & Chemical Res 生理活性ペプチド徐放性製剤
US20040047910A1 (en) * 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
US7034037B2 (en) * 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
US6967234B2 (en) * 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
US7030127B2 (en) * 2001-06-29 2006-04-18 Ethicon, Inc. Composition and medical devices utilizing bioabsorbable polymeric waxes
JP2005502426A (ja) 2001-09-14 2005-01-27 フランシス ジェイ マーティン 治療剤の徐放のための微細加工ナノ細孔デバイス
JP2005518430A (ja) * 2001-11-19 2005-06-23 ベクトン・ディキンソン・アンド・カンパニー 微粒子形態の薬剤組成物
US7005136B2 (en) * 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US7368125B2 (en) * 2002-06-05 2008-05-06 Ethicon, Inc. Amphiphilic polymers for medical applications
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7026374B2 (en) * 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US6872799B2 (en) * 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
US6866860B2 (en) * 2002-12-19 2005-03-15 Ethicon, Inc. Cationic alkyd polyesters for medical applications
US20040120981A1 (en) * 2002-12-20 2004-06-24 Aruna Nathan Crosslinked alkyd polyesters for medical applications
USD491183S1 (en) 2003-06-04 2004-06-08 Logitech Europe S.A. Game pad
WO2005000312A1 (ja) * 2003-06-27 2005-01-06 Otsuka Pharmaceutical Co., Ltd. 薬物徐放性粒子及びその製法
EP1686963A1 (en) * 2003-10-27 2006-08-09 PSivida Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
KR100486028B1 (ko) * 2004-04-20 2005-05-03 주식회사 펩트론 단백질 함유 서방성 리피드 임플란트 및 이의 제조방법
US8541028B2 (en) * 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
WO2006033948A2 (en) 2004-09-17 2006-03-30 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as saib
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5276448B2 (ja) * 2005-12-22 2013-08-28 オークウッド ラボラトリーズ，エル．エル．シー． 昇華可能な持続放出デリバリーシステム及びその製造方法
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
CA2706931C (en) 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
ES2441550T3 (es) * 2007-12-21 2014-02-05 Ludwig-Maximilians-Universität Dispositivos extruidos con forma de varilla para la Iiberación controlada de sustancias biológicas a humanos y animales
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9532946B2 (en) 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
AU2017292791B2 (en) 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
IE65045B1 (en) * 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
TW209174B (enExample) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IL103275A0 (en) * 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
YU87892A (sh) * 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
JPH06219960A (ja) * 1993-01-25 1994-08-09 Takeda Chem Ind Ltd 生理活性ポリペプチド含有組成物の製造法
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法

Also Published As

Publication number Publication date
CN1104488A (zh) 1995-07-05
DE69401691T2 (de) 1997-07-17
KR950005329A (ko) 1995-03-20
US5750100A (en) 1998-05-12
KR100338400B1 (ko) 2002-11-22
JPH07112940A (ja) 1995-05-02
DE69401691D1 (de) 1997-03-20
ATE148625T1 (de) 1997-02-15
EP0640336B1 (en) 1997-02-05
CN1105557C (zh) 2003-04-16
US5628993A (en) 1997-05-13
EP0640336A1 (en) 1995-03-01
DK0640336T3 (da) 1997-04-01
CA2130868A1 (en) 1995-02-27

Similar Documents

Publication Publication Date Title
TW282403B (enExample)
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ZA896149B (en) Pharmaceutical formulation for the treatment of diabetes mellitus
ES2009346A6 (es) Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
EP0252290A3 (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
AU6819294A (en) Oral drug delivery compositions and methods
ATE177645T1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
AU8018187A (en) Pharmaceutical compositions of recombinant interleukin-2 and formulation process
NZ228836A (en) Solid pharmaceutical composition having antacid properties
NO176082C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel
CA2058835A1 (en) Stable pharmaceutical composition and method for its production
IT1235053B (it) Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
ZA898331B (en) Pharmaceutical compositions
IL79816A0 (en) Pharmaceutical composition comprising a drug-polymer matrix
DE69837997D1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
CA2025070A1 (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof
IL105215A0 (en) 9-fluoro-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acids and their esters,their preparation and pharmaceutical compositions containing them
NZ236474A (en) 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
BE1002504A3 (fr) Preparation medicamenteuse a base de derives d'esters d'hecogenine et leur utilisation pour le traitement de l'hyperplasie prostatique benigne.
IL105214A0 (en) 7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acids and their esters,their preparation and pharmaceutical compositions containing them
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
ITRM910070A1 (it) Derivati degli acidi dicarbossilici aventi da sei a dodici atomi di carbonio ed impiego di tali derivati e degli acidi stessi per la preparazione di composizioni farmaceutiche atte all'alimentazione enterale parenterale.
ATE136778T1 (de) Oral anzuwendende arzneimittel dapiprazol enthaltend
IL82639A0 (en) Transdermal pharmaceutical composition